Page 97 - Read Online

Page 6 of 6 Vander Borght et al. J Cancer Metastasis Treat 2019;5:57 I http://dx.doi.org/10.20517/2394-4722.2019.0010

4. Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC. Small cell lung cancer: have we made any progress over the last 25 years?
Oncol 2007;12:1096-104.
5. Vander Borght A, Duysinx M, Broers JLV, Ummelen M, Falkenberg FW, et al. The 180 splice variant of NCAM-containing exon 18-is
specifically expressed in small cell lung cancer cells. Transl Lung Cancer Res 2018;7:376-88.
6. Kim JY, Hong SM, Ro JY. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol 2017;29:11-6.
7. Rekhtman N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med 2010;134:1628-38.
8. Travis WD. Advances in neuroendocrine lung tumors. Ann Oncol 2010;21 Suppl 7:vii65-71.
9. Lane RD. A short-duration polyethylene glycol fusion technique for increasing production of monoclonal antibody-secreting hybridomas.
J Immunol Methods 1985;81:223-8.
10. Lehman JM, Gwin ME, Massion PP. Immunotherapy and targeted therapy for small cell lung cancer: there is hope. Curr Oncol Rep
2017;19:49.
11. Mamdani H, Induru R, Jalal SI. Novel therapies in small cell lung cancer. Transl Lung Cancer Res 2015;4:533-44.
12. Hendriks LEL, Menis J, Reck M. Prospects of targeted and immune therapies in SCLC. Expert Rev Anticancer Ther 2018;28:1-17.
13. Almodovar K, Iams WT, Meador CB, Zhao Z, York S, et al. Longitudinal cell-free DNA analysis in patients with small cell lung cancer
reveals dynamic insights into treatment efficacy and disease relapse. J Thorac Oncol 2018;13:112-23.
14. Foy V, Fernandez-Gutierrez F, Faivre-Finn C, Dive C, Blackhall F. The clinical utility of circulating tumour cells in patients with small
cell lung cancer. Transl Lung Cancer Res 2017;6:409-17.
15. Choi DS, Kim DK, Kim YK, Gho YS. Proteomics of extracellular vesicles: exosomes and ectosomes. Mass Spectrom Rev 2015;34:474-
90.
16. Kaufmann O, Georgi T, Dietel M. Utility of 123C3 monoclonal antibody against CD56 (NCAM) for the diagnosis of small cell
carcinomas on paraffin sections. Hum Pathol 1997;28:1373-8.
17. Kibbelaar RE, Moolenaar KE, Michalides RJ, Van Bodegom PC, Vanderschueren RG, et al. Neural cell adhesion molecule expression,
neuroendocrine differentiation and prognosis in lung carcinoma. Eur J Cancer 1991;27:431-5.
18. Greening DW, Xu R, Ji H, Tauro BJ, Simpson RJ. A protocol for exosome isolation and characterization: evaluation of ultracentrifugation,
density-gradient separation, and immunoaffinity capture methods. Methods Mol Biol 2015;1295:179-209.
19. Boerman OC, Mijnheere EP, Broers JL, Vooijs GP, Ramaekers FC. Biodistribution of a monoclonal antibody (RNL-1) against the neural
cell adhesion molecule (NCAM) in athymic mice bearing human small-cell lung-cancer xenografts. Int J Cancer 1991;48:457-62.
20. Schol DJ, Mooi WJ, van der Gugten AA, Wagenaar SS, Hilgers J. Monoclonal antibody 123C3, identifying small cell carcinoma
phenotype in lung tumours, recognizes mainly, but not exclusively, endocrine and neuron-supporting normal tissues. Int J Cancer Suppl
1988;2:34-40.
21. Gerardy-Schahn R, Eckhardt M, Ledermann J, Kemshead JT. Topography of NCAM antigenic epitopes recognized by SCLC-cluster-1
antibodies. A consensus view. Int J Cancer Suppl 1994;8:27-9.